100
Participants
Start Date
August 31, 2011
Primary Completion Date
February 28, 2014
Study Completion Date
February 28, 2014
Placebo
Matching placebo to secukinumab I.V.
Secukinumab
In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
Novartis Investigative Site, Brussels
Novartis Investigative Site, Kortrijk
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Statesville
Novartis Investigative Site, Marietta
Novartis Investigative Site, Fleming Island
Novartis Investigative Site, Coral Gables
Novartis Investigative Site, Miami
Novartis Investigative Site, Clearwater
Novartis Investigative Site, Pinellas Park
Novartis Investigative Site, Venice
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Herne
Novartis Investigative Site, South Bend
Novartis Investigative Site, Frankfurt am Main
Novartis Investigative Site, Springfield
Novartis Investigative Site, Oklahoma City
Novartis Investigative Site, San Antonio
Novartis Investigative Site, München
Novartis Investigative Site, Phoenix
Novartis Investigative Site, Tuscon
Novartis Investigative Site, Albuquerque
Novartis Investigative Site, Anahiem
Novartis Investigative Site, Moscow
Novartis Investigative Site, Yaroslavl
Novartis Investigative Site, Yaroslavl
Novartis Investigative Site, Tver'
Novartis Investigative Site, Petrozavodsk
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Smolensk
Novartis Investigative Site, Nizhny Novgorod
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Manchester
Novartis Investigative Site, Belfast
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY